The proliferation of cervical cancer is promoted by miRNA-125b through the regulation of the HMGA1
Authors Sun B, Zhang Y, Zhou L, Yin L, Li F, Li C, Xia J
Received 11 December 2018
Accepted for publication 19 February 2019
Published 11 April 2019 Volume 2019:12 Pages 2767—2776
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Aruna Narula
Peer reviewer comments 3
Editor who approved publication: Dr Sanjeev Srivastava
Bingmei Sun, Ying Zhang, Lianxiang Zhou, Linin Yin, Fei Li, Chao Li, Jiayu Xia
Department of Gynaecology and Obstetrics, Linyi Central Hospital, Linyi 276400, Shandong Province, China
Background: It has been reported that miRNA-125b is associated with carcinogenesis and development of several different kinds of cancers. Nevertheless, there is no clarity regarding the significance and mechanism of action of miR-125b in clinical practice for cervical cancer (CC).
Materials and methods: In the current investigation, the expression of miR-125b in cervical clinical specimens and CC cell lines was analyzed via real-time quantitative PCR, and the relationship of miR-125b with the chromatin-associated protein high mobility group A (HMGA1) expression and clinicopathological parameters of CC patients was explored.
Results: The results indicated that miR-125b expression was remarkably upregulated in CC cell lines as well as in the tissues of humans. miR-125b overexpression was significantly related to a decrease in HMGA1 expression, progression-free survival, overall survival, and prognosis as well. Besides, knockdown of miR-125b inhibited proliferation and colony formation in SW756 and C4-1 cells, where the 3'-UTR of HMGA1 mRNA was directly targeted. Moreover, PI3K/Akt pathway was regulated by miR-125b through suppression of HMGA1.
Conclusion: These findings illustrated that a new regulatory role of HMGA1 is involved in the progression of CC. Our data demonstrated that miR-125b could play a critical role in the carcinogenesis and progression of CC, revealing that miR-125b might serve as a potential new target for treating CC.
Keywords: cervical cancer, CC, miR-125b, high mobility group A, HMGA1, progression-free survival, PFS, overall survival, OS, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]